pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›LP-310
drug · small molecule
save

LP-310

Phase 2updated 3mo ago
by $LIPO LIPELLA PHARMACEUTICALS INC.🔗 ChEMBL
Phase 2
community read0 votes

🐶 often sniffed alongside

top 8
  • tagApproval16 co-mentions · 8 sources
  • companyAstellas Pharma US Inc8 co-mentions · 2 sources
  • tagSmall Molecule8 co-mentions · 8 sources
  • companyAstellas Pharma Inc8 co-mentions · 2 sources
  • drug386574 co-mentions · 2 sources
  • drugTACROLIMUS4 co-mentions · 2 sources
  • tagRecall4 co-mentions · 2 sources
  • companyBiocon Pharma Ltd3 co-mentions · 3 sources

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 9 approved and 18 investigational indications.

targets

Peptidyl-prolyl cis-trans isomerase FKBP1A

all catalysts(0)

nothing on the calendar yet

Trials studying LP-310

  • phase3A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)recruitingn=180
  • phase2Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uveitisrecruitingn=20
  • phase3A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathyactive not recruitingn=178
  • phase3Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)recruitingn=176
  • phase2CC-101 (f/k/a NR1) Neural Stem Cell Transplantation for Adults With Chronic Ischemic Strokenot yet recruitingn=36
  • phase4Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplantsactive not recruitingn=60
  • phase3A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitorrecruitingn=636
  • phase3A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantationrecruitingn=526
more trials →

News(4)

  • With $263M, LifeMine unearths a new drug for organ transplants
    Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
    biopharma_dive · 9d ago
  • LifeMine raises $263M in mission to improve organ transplant aftercare
    Patients who receive an organ transplant must take difficult immuno-suppressive medicines for the rest of their lives. LifeMine Therapeutics wants to offer a safer alternative.
    biospace · 9d ago
  • ‘Greg, you’ve got to bring back this platform’: How LifeMine won over Gates and Bezos for $188M series E
    A little over a year ago, LifeMine Therapeutics laid off staff and put its fungus-based platform on ice to focus its dwindling resources on its lead asset. Now, the Massachusetts biotech is shaking…
    fiercebiotech · 9d ago
  • Type 1 diabetes pipeline making ‘remarkable progress’ toward insulin independence
    After the trailblazing approval of Sanofi’s Tzield for stage 3 type 1 diabetes, several companies, including SAB Biotherapeutics and Eledon Pharmaceuticals, are vying for a spot in the landscape wi…
    biospace · 26d ago
trade names
Adoport, Advagraf, Astagraf xl, Capexion, Envarsus, Envarsus xr
generic
tacrolimus
MOA
FK506-binding protein 1A inhibitor
indication
Erosive Oral Lichen Planus
phase
phase_2
Data sources
ClinicalTrials.gov · OpenTargets
last refreshed 32m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?